Johnson Financial Group LLC acquired a new position in scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 85,184 shares of the company's stock, valued at approximately $302,000. Johnson Financial Group LLC owned approximately 0.17% of scPharmaceuticals at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bank of New York Mellon Corp increased its stake in shares of scPharmaceuticals by 8.8% in the 4th quarter. Bank of New York Mellon Corp now owns 75,174 shares of the company's stock worth $266,000 after purchasing an additional 6,051 shares in the last quarter. Rice Hall James & Associates LLC increased its stake in scPharmaceuticals by 59.2% in the 4th quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company's stock worth $3,503,000 after buying an additional 367,970 shares in the last quarter. Rhumbline Advisers increased its stake in scPharmaceuticals by 20.1% in the 4th quarter. Rhumbline Advisers now owns 42,554 shares of the company's stock worth $151,000 after buying an additional 7,112 shares in the last quarter. Legato Capital Management LLC purchased a new stake in scPharmaceuticals in the 4th quarter worth $37,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in scPharmaceuticals in the 4th quarter worth $38,000. 89.52% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
SCPH has been the subject of a number of analyst reports. Craig Hallum cut their price target on scPharmaceuticals from $16.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, November 14th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of scPharmaceuticals in a research note on Thursday, November 14th.
View Our Latest Stock Report on scPharmaceuticals
scPharmaceuticals Price Performance
SCPH stock traded up $0.04 during trading on Friday, reaching $3.28. The company's stock had a trading volume of 396,602 shares, compared to its average volume of 281,095. The company's fifty day moving average is $3.40 and its 200-day moving average is $4.00. scPharmaceuticals Inc. has a 1 year low of $3.08 and a 1 year high of $6.28. The company has a market capitalization of $164.13 million, a P/E ratio of -1.73 and a beta of 0.11. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66.
scPharmaceuticals Profile
(
Free Report)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Further Reading
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
